Press Releases

    Print Page  Close Window
BioMed Realty Trust, Inc. Announces Exercise of Over-Allotment Option

SAN DIEGO, June 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today that its underwriters have exercised their over- allotment option in full to purchase an additional 1,972,500 shares of common stock to be offered at the public offering price of $22.50 per share, all of which are being sold by the company. In total, the company sold 15,122,500 shares of common stock, which will raise gross offering proceeds of $340.3 million.

Raymond James & Associates Inc. acted as the sole lead book-running manager, with KeyBanc Capital Markets, Wachovia Capital Markets LLC, Friedman Billings Ramsey & Co. Inc., Legg Mason Wood Walker Inc. and RBC Capital Markets Corp. acting as co-managers of the offering.

The offering of these securities is made only by means of a prospectus, copies of which may be obtained by contacting Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL 33716.

The registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of such securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. Our tenants include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. Additional information is available at http://www.biomedrealty.com .

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: the company's ability to close this public offering on the terms described in this release, or at all, and if this offering closes, the level of the company's share price, which may decline; general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the Boston or California regions; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.

John F. Wilson, II, Chief Financial Officer, BioMed Realty Trust, +1-858-485-9840

http://www.prnewswire.com